Stock listing

NYSE:NUVB Nuvation Bio Inc. Stock

Home listing (NYSE) of Nuvation Bio Inc.

Follow Nuvation Bio Inc. into a list and get an email when it puts out news.

Share price · NYSE:NUVB

$4.75 USD +0.07 (+1.5%)

Close on Oct 15, 2026

Nuvation Bio Inc. logo
Ticker
NYSE:NUVB
Asset type
Stock
Exchange
NYSE
Currency
USD

What changed lately

Calls

Replays

  • Nuvation Bio (NYSE:NUVB) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:00 AM ET

    Watch Transcript

  • Nuvation Bio (NYSE:NUVB) Q1 2026 Earnings Call

    Mon, May 04, 2026 · 4:30 PM ET

    Watch Transcript

  • Nuvation Bio (NYSE:NUVB) Q3 2025 Earnings Call

    Mon, Nov 03, 2025 · 4:30 PM ET

    Watch Transcript

Latest news

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

Sep 16, 2026

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

Sep 15, 2026

Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

Aug 20, 2026

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 6, 2026

Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Aug 4, 2026

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Jul 22, 2026

Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma

Jul 20, 2026

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

Jul 6, 2026

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom

Jun 29, 2026

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

Jun 25, 2026

All Nuvation Bio Inc. news

Financings

  • 0.75% Convertible Senior Notes due 2032

    Jul 6, 2026

    Closed: US$287.5M raised

    Use of proceeds: Pay about $2.2 million for additional capped call transactions; remainder for general corporate purposes including working capital and operating expenses

    Closed Jul 6, 2026

Read by 6ix AI from the company's releases

Decks

Nuvation Bio Inc. on 6ix

News releases
33 in the last 12 months · 52 in all · newest Sep 16, 2026 · oldest 2025
Calls
5 calls with a replay · 5 with a transcript · latest Aug 6, 2026
Decks
16 decks · latest Aug 6, 2026

Where Nuvation Bio Inc. is listed

ListingExchangeCountryCurrency
NYSE:NUVB · Home listing · This pageNYSEUnited StatesUSD
BOATS:NUVBBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Nuvation Bio Inc.